Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …

The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide
interdisciplinary guidance on the management of immune-related adverse events (irAEs) …

Background & Aims Immune checkpoint inhibitors (ICIs) have transformed the treatment
landscape for oncology, leading to durable remissions in a subset of patients, but also a …

Background & Aims The pathogenesis of immune checkpoint inhibitor (ICI)–colitis remains
incompletely understood. We sought to identify key cellular drivers of ICI-colitis and their …

Hepatocellular carcinoma (HCC) is one of the world's deadliest and fastest-growing tumors,
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …